Evidence map›Paper›PMID 37337728›Full record

Trial reportClinical trials (London, England)2023

A comparison of different population-level summary measures for randomised trials with time-to-event outcomes, with a focus on non-inferiority trials.

Matteo Quartagno, Tim P Morris, Duncan C Gilbert, Ruth E Langley, Matthew G Nankivell, Mahesh Kb Parmar, Ian R White

Abstract readEquivalence TrialRandomized Controlled Trial
In one paragraph

Trial report in Clinical trials (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Matteo QuartagnoMRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.ORCID 0000-0003-4446-0730
Tim P MorrisMRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.ORCID 0000-0001-5850-3610
Duncan C GilbertMRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.
Ruth E LangleyMRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.
Matthew G NankivellMRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.
Mahesh Kb ParmarMRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.
Ian R WhiteMRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.ORCID 0000-0002-6718-7661

Funding

Medical Research Council MC_UU_00004/07Medical Research Council MC_UU_00004/09
6 · The paper itself

Abstract

backgroundThe population-level summary measure is a key component of the estimand for clinical trials with time-to-event outcomes. This is particularly the case for non-inferiority trials, because different summary measures imply different null hypotheses. Most trials are designed using the hazard ratio as summary measure, but recent studies suggested that the difference in restricted mean survival time might be more powerful, at least in certain situations. In a recent letter, we conjectured that differences between summary measures can be explained using the concept of the non-inferiority frontier and that for a fair simulation comparison of summary measures, the same analysis methods, making the same assumptions, should be used to estimate different summary measures. The aim of this article is to make such a comparison between three commonly used summary measures: hazard ratio, difference in restricted mean survival time and difference in survival at a fixed time point. In addition, we aim to investigate the impact of using an analysis method that assumes proportional hazards on the operating characteristics of a trial designed with any of the three summary measures.

methodsWe conduct a simulation study in the proportional hazards setting. We estimate difference in restricted mean survival time and difference in survival non-parametrically, without assuming proportional hazards. We also estimate all three measures parametrically, using flexible survival regression, under the proportional hazards assumption.

resultsComparing the hazard ratio assuming proportional hazards with the other summary measures not assuming proportional hazards, relative performance varies substantially depending on the specific scenario. Fixing the summary measure, assuming proportional hazards always leads to substantial power gains compared to using non-parametric methods. Fixing the modelling approach to flexible parametric regression assuming proportional hazards, difference in restricted mean survival time is most often the most powerful summary measure among those considered.

conclusionWhen the hazards are likely to be approximately proportional, reflecting this in the analysis can lead to large gains in power for difference in restricted mean survival time and difference in survival. The choice of summary measure for a non-inferiority trial with time-to-event outcomes should be made on clinical grounds; when any of the three summary measures discussed here is equally justifiable, difference in restricted mean survival time is most often associated with the most powerful test, on the condition that it is estimated under proportional hazards.

Indexed as

Research DesignComputer SimulationHumansProportional Hazards ModelsSample SizeSurvival AnalysisTime Factorsdifference in survivalestimandshazard ratioNon-inferioritypopulation-level summary measuresrestricted mean survival time

Identifiers

PMID37337728
PMCPMC7615295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.